Due to the disadvantages of biological experiments as being time-consuming and of high cost, identification of ADME (absorption, distribution, metabolism, and excretion) properties by in silico tools has now become an inevitable paradigm in pharmaceutical research. In this study, three ADME-related models, namely, the evaluation of oral bioavailability (OB), Caco-2 permeability, and drug-likeness (DL), are employed to identify the potential bioactive compounds of DXP [33 (
link)].
Oral Bioavailability. OB prescreening is used to determine the fraction of the oral dose of bioactive compound which reaches systemic circulation in the TCM remedy. Here, a reliable in silico model OBioavail 1.1 [34 (
link)] which integrates the metabolism (P450 3A4) and transport (P-glycoprotein) information was employed to calculate the OB values of herbal ingredients.
Caco-2 Permeability. The Caco-2 cell monolayers are widely applied as standard permeability-screening assay for prediction of the compound's intestinal absorption and fraction of the oral dose absorbed in humans [35 (
link)]. The Caco-2 cell permeation values of all molecules are calculated by in silico model using the VolSurf approach [36 ].
Drug-Likeness Evaluation. Drug-likeness is a qualitative profile used in drug design to evaluate whether a compound is chemically suitable for the drug, and how drug-like a molecule is with respect to parameters affecting its pharmacodynamic and pharmacokinetic profiles which ultimately impact its ADME properties [37 (
link)]. In order to identify drug-like compounds, we apply a database-dependent model using the Tanimoto coefficient to calculate the DL (see (
1)) of each compound in DXP.
𝓍 represents the molecular parameters of herbal ingredients and
𝓎 represents the average molecular properties in DrugBank database (available online:
http://www.drugbank.ca).
In this work, the compounds of OB ≥ 30%, Caco-2 > −0.4, and DL ≥ 0.18 are selected for subsequent research, and others are excluded.
According to these indexes, several compounds are included: ergosterol peroxide, ethyl oleate (NF), glabridin, glycyrrhetinic acid, linoleyl acetate, longikaurin A, mairin, mandenol, MOL000273, MOL001910, 508-02-1, 64997-52-0, 8
β-ethoxy atractylenolide III, pachymic acid, paeonidanin, palbinone, saikosaponin C, beta-sitosterol, supraene, trametenolic acid, troxerutin,
α-amyrin, MOL000285, 4-O-methylpaeoniflorin, glabrene, poricoic acid A, glycyrrhizin, sudan III, ZINC02816192, kaempferol, 7,9(11)-dehydropachymic acid, licochalcone G, paeoniflorgenone, areapillin, quercetin, stigmasterol, isoliquiritigenin, (+)-anomalin, isorhamnetin, vestitol, crocetin, 113269-36-6,
α-spinasterol, licochalcone A, 113269-37-7, 3
β-acetoxyatractylone, licoricone, 113269-39-9, petunidin, hederagenin, dehydroeburicoic acid, licochalcone B, ergosta-7,22E-dien-3beta-ol, MOL000280, MOL000287, mudanpioside H, NSC684433, octalupine, 18103-41-8, formononetin, 1-methoxyphaseollidin, paeoniflorin, glycyrin, ammidin, poricoic acid B, poricoic acid C, sainfuran, sitosterol, isoimperatorin, isolicoflavonol, cerevisterol, 3-methylkempferol, licoisoflavone B, cubebin, and (+)-catechin, 3′-hydroxy-4′-O-methylglabridin.
Yang K., Zeng L, & Ge J. (2018). Exploring the Pharmacological Mechanism of Danzhi Xiaoyao Powder on ER-Positive Breast Cancer by a Network Pharmacology Approach. Evidence-based Complementary and Alternative Medicine : eCAM, 2018, 5059743.